Meeting NewsVideo

VIDEO: Less than 50% of patients treated with allopurinol reach uric acid target

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Machelle Manuel, PhD, vice president of medical scientific affairs at Ironwood Pharmaceuticals, discussed study findings that analyzed physician, patient and treatment characteristics related to patients with gout treated with allopurinol. The study also determined the proportion of patients who reached their serum uric acid target by allopurinol dose.

According to Manuel, although allopurinol is approved for up to 800 mg in the United States, and 900 mg in the European Union, most patients were treated with 300 mg or less per day. Further, less than 50% of patients achieved the serum uric acid target of less than 6 mg/dL at any dose of allopurinol, and that those receiving higher doses were not more likely to reach that target.

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Machelle Manuel, PhD, vice president of medical scientific affairs at Ironwood Pharmaceuticals, discussed study findings that analyzed physician, patient and treatment characteristics related to patients with gout treated with allopurinol. The study also determined the proportion of patients who reached their serum uric acid target by allopurinol dose.

According to Manuel, although allopurinol is approved for up to 800 mg in the United States, and 900 mg in the European Union, most patients were treated with 300 mg or less per day. Further, less than 50% of patients achieved the serum uric acid target of less than 6 mg/dL at any dose of allopurinol, and that those receiving higher doses were not more likely to reach that target.

    See more from American College of Rheumatology Annual Meeting